Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

The "Diabetes Monitoring, Treatment and Drug Delivery Market Size, Share & Trends Analysis | United States | 2025-2031 | MedSuite | Includes: Insulin & GLP-1, Continuous Glucose Monitoring and 7 more" ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that Novo's next-generation CagriSema ...

Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG (RHHVF – Research Report) on March 17 and set a price target of CHF315.00. The company’s shares closed yesterday ...

Justine Ross. Image Credit: Michigan Medicine A common and serious side effect of diabetes is diabetic ketoacidosis, which arises when the body is unable to produce enough insulin. The body begins ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Type 2 diabetes can cause complications if not managed properly. These include nerve damage, kidney disease, and stroke. You can help prevent these by having regular checkups with your doctor and ...

To make a type 2 diabetes diagnosis, doctors can use several different blood tests. You’ll typically need to be tested at least twice to confirm a diagnosis. Most people are tested for diabetes ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming ...

Roche shares gained 5.5%. Zealand is testing petrelintide in overweight or obese individuals without type 2 diabetes in a mid-stage study. Petrelintide belongs to a class of drugs known as long ...